BridgeBio Oncology Therapeutics, Inc. - 8-K Filing
Michelle Doig resigned from the Board of Directors of BridgeBio Oncology Therapeutics effective June 16, 2026, following her term as a Class I director and not due to any disagreements with the company. At the Annual Meeting on that date, stockholders elected Peter Lebowitz and Frank P. McCormick as Class I directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm. (Items: 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offic, 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $BBOT